[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336981-105":59,"doc-detail-336981-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","o-glcnacylation-of-enolase-1-serves-as-a-dual-regulator-of-aerobic-glycolysis-and-immune-evasion-in-colorectal-cancer-abstract","O-GlcNAcylation of enolase 1 serves as a dual regulator of aerobic glycolysis and immune evasion in colorectal cancer - abstract","","Aerobic glycolysis and immune evasion are central hallmarks of colorectal cancer, yet their mechanistic connection remained unclear. The study demonstrates that enolase-1 (ENO1) is dynamically O-GlcNAcylated, and differential glycosylation coordinates both processes. Glycosylation at threonine 19 enhances glycolytic activity via active dimer formation, while serine 249 glycosylation blocks PD-L1 interaction with STUB1, stabilizing PD-L1. Dual blockade synergizes with PD-L1 monoclonal antibody therapy to promote antitumor immunity. Clinically, ENO1 O-GlcNAc levels correlate positively with PD-L1 in colorectal tumors.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/o-glcnacylation-of-enolase-1-serves-as-a-dual-regulator-of-aerobic-glycolysis-and-immune-evasion-in-colorectal-cancer-abstract/336981/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/o-glcnacylation-of-enolase-1-serves-as-a-dual-regulator-of-aerobic-glycolysis-and-immune-evasion-in-colorectal-cancer-abstract/336981.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main finding about ENO1 in colorectal cancer?","Question",{"text":112,"@type":113},"EN0-1 is dynamically modified by O-GlcNAcylation, and differential glycosylation enables ENO1 to regulate both aerobic glycolysis and immune evasion in colorectal cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does O-GlcNAcylation at T19 affect glycolysis?",{"text":117,"@type":113},"Glycosylation of ENO1 at threonine 19 promotes its glycolytic activity through formation of active dimers, increasing glucose metabolism.",{"name":119,"@type":110,"acceptedAnswer":120},"How does O-GlcNAcylation at S249 influence immune evasion?",{"text":121,"@type":113},"Glycosylation of ENO1 at serine 249 inhibits interaction with PD-L1 and reduces PD-L1 association with STUB1, leading to PD-L1 stabilization and immune escape.",{"name":123,"@type":110,"acceptedAnswer":124},"Why is targeting both glycosylation sites therapeutically important?",{"text":125,"@type":113},"Eliminating glycosylation at both sites synergizes with PD-L1 monoclonal antibody therapy, strengthening antitumor immune responses and reducing tumor growth.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},336981,1790878472,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":41,"preview_page_count":19,"preview_urls":149},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","O-GlcNAcylation of enolase 1 serves as a dual regulator of aerobic glycolysis and immune evasion in colorectal cancer  \nQiang Zhua, b,1,2, Jingchao Lia, b,1, Haofan Sunc, Zhiya Fanc , Jiating Hud, Siyuan Chaid , Bingyi Lind , Liming Wud, Weijie Qinc, Yong Wanga, b ,  \nLinda C. Hsieh-Wilsone , and Wen Yia, b,d,2 Affiliations are included on p. 11.  \nEdited by Gerald W. Hart, The University of Georgia, Athens, GA; received April 29, 2024; accepted September 26, 2024 by Editorial Board Member Herbert Levine  \nAerobic glycolysis and immune evasion are two key hallmarks of cancer. However, how these two features are mechanistically linked to promote tumor growth is not well understood. Here, we showthat the glycolytic enzyme enolase-1 (ENO1) is dynamically modified with an O-linked β-N-acetylglucosamine (O-GlcNAcylation), and simultaneously regulates aerobic glycolysis and immune evasion via differential glycosylation. Glycosylation of threonine 19 (T19) on ENO1 promotes its glycolytic activity via the formation of active dimers. On the other hand, glycosylation of serine 249 (S249) on ENO1 inhibits its interaction with PD-L1, decreases association of PD-L1 with the E3 ligase STUB1, resulting in stabilization of PD-L1. Consequently, blockade ofT19 glycosylation on ENO1 inhibits glycolysis, and decreases cell proliferation and tumor growth. Blockade ofS249 glycosylation on ENO1 reduces PD-L1 expression and enhances T cell–mediated immunity against tumor cells. Notably, elimination of glycosylation at both sites synergizes with PD-L1 monoclonal antibody therapy to promote antitumor immune response. Clinically, ENO1 glycosylation levels are up-regulated and show a positive correlation with PD-L1 levels in human colorectal cancers. Thus, our findings provide a mechanistic understanding of how O-GlcNAcylation bridges aerobic glycolysis and immune evasion to promote tumor growth, suggesting effective therapeutic opportunities.  \nenolase | O-GlcNAcylation | glycolysis | immune evasion | cancer  \nO-GlcNAcylation is a dynamic monosaccharide modification on serine or threonine hydroxyl moieties of intracellular proteins (1) . The cycle of O-GlcNAcylation on protein substrates is mediated by a set of enzymes. O-GlcNAc transferase (OGT) is responsible for the addition of O-GlcNAc while O-GlcNAcase (OGA) catalyzes the removal of the GlcNAc moiety (2, 3). It is reported that thousands of proteins in cells are O-GlcNAcylated, which plays important roles in transcription, translation, cell cycle, and metabolism (4–6) . The disorder of O-GlcNAcylation in cells is closely related to human diseases such as diabetes, cardiovascular diseases, and cancers (7–9). Mounting studies indicated that global O-GlcNAcylation is elevated in various types of cancer, and its overexpression links to the poor survival of patients (10–12). However, the molecular mechanisms of O-GlcNAcylation involved in regulating tumor growth and immune evasion remain elusive.  \nThe ability for immune evasion is a common feature of cancer cells (13). The programmed death ligand 1 (PD-L1), a key immune checkpoint protein on cancer cell surfaces, plays a crucial role in cancer immune evasion (14, 15). The binding of PD-L1 with its receptor PD-1 on cytotoxic T lymphocytes inducesT cell exhaustion and weakens antitumor activity (16, 17) . In recent years, immune checkpoint inhibitors (ICIs) have underscored the profound therapeutic efficacy by disrupting the interaction between PD-L1 and PD-1 for the treatment of advanced melanoma, non–small cell lung cancer, renal cell carcinoma, and head and neck cancer (18, 19) . However, the majority of patients do not achieve durable remission with the therapy, and some solid tumors are completely refractory to the treatment (20). Accumulated evidence demonstrated that the level of PD-L1 expression in cancer cells is a critical factor for assessing the efficacy of anti-PD-L1/PD-1 therapy (16, 21) . Thus, a comprehensive understanding of PD-L1 expres","cbCaipcqvAB3duve","https://ap.wps.com/l/cbCaipcqvAB3duve","pdf",8402697,12,"English","# Background\n## O-GlcNAcylation and its roles\n## Immune evasion via PD-L1\n# ENO1 as a dual regulator\n## T19 glycosylation and aerobic glycolysis\n## S249 glycosylation and PD-L1 stabilization\n# Therapeutic implications\n## Synergy with PD-L1 monoclonal antibodies\n## Clinical correlation in colorectal cancer","[{\"question\":\"What is the main finding about ENO1 in colorectal cancer?\",\"answer\":\"EN0-1 is dynamically modified by O-GlcNAcylation, and differential glycosylation enables ENO1 to regulate both aerobic glycolysis and immune evasion in colorectal cancer.\"},{\"question\":\"How does O-GlcNAcylation at T19 affect glycolysis?\",\"answer\":\"Glycosylation of ENO1 at threonine 19 promotes its glycolytic activity through formation of active dimers, increasing glucose metabolism.\"},{\"question\":\"How does O-GlcNAcylation at S249 influence immune evasion?\",\"answer\":\"Glycosylation of ENO1 at serine 249 inhibits interaction with PD-L1 and reduces PD-L1 association with STUB1, leading to PD-L1 stabilization and immune escape.\"},{\"question\":\"Why is targeting both glycosylation sites therapeutically important?\",\"answer\":\"Eliminating glycosylation at both sites synergizes with PD-L1 monoclonal antibody therapy, strengthening antitumor immune responses and reducing tumor growth.\"}]","O-GlcNAcylation of enolase 1 serves as a dual regulator of aerobic glycolysis and immune evasion in colorectal cancer - abstract | PDF",1790017275,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aff36ce29bba21f2e7d3c2ebf8be4fab.webp",983,1316,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/130cca5504a3e4d265381cbee63e32a4.webp",982,1315,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/43368beafa06fffa26bb160c386b79f6.webp",981,1313,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a339b7ce96973ba988a4aaa4328b5271.webp",980,1312]